{"entity":{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","aka":["duocarmycins","seco-DUBA"],"tldr":"DNA alkylator payloads chemically damage DNA regardless of whether the cell is dividing, and are aimed at slow-growing and resistant tumours.","summary":"DNA alkylator payloads, chiefly the duocarmycins and seco-DUBA, chemically damage DNA whether or not the cell is dividing, and they are aimed at slow-growing and resistant tumours. In preclinical models duocarmycin-type alkylators act independently of the cell cycle and are not cross-resistant with tubulin or topoisomerase payloads, which is the attraction. Clinical translation has nonetheless been slow: trastuzumab duocarmazine reached phase 3 but was not approved. The class belongs to the Antibody-drug conjugate (ADC) technology and the Payload (ADC) term, and it is referenced by the specific payload record Duocarmycin (seco-DUBA) and by the pathway on base excision repair, PARP and alkylation damage, which describes how cells respond to this kind of lesion.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Duocarmycin","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Duocarmycin"}],"tags":[],"related":["duocarmycin"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/dna-alkylator-payloads/","neighbours":{"term":[{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"pathway":[{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/"}]}}